Loading...
BVMFPFRM3
Market cap120mUSD
Dec 23, Last price  
6.09BRL
1D
-2.09%
1Q
7.98%
Jan 2017
-23.01%
IPO
-73.49%
Name

Profarma Distribuidora de Produtos Farmaceuticos SA

Chart & Performance

D1W1MN
BVMF:PFRM3 chart
P/E
10.61
P/S
0.09
EPS
0.57
Div Yield, %
4.18%
Shrs. gr., 5y
0.92%
Rev. gr., 5y
15.19%
Revenues
8.66b
+10.82%
1,519,577,0001,728,608,0002,268,874,0002,535,516,0002,578,291,0002,626,119,0003,317,048,0003,383,636,0003,470,310,0003,449,124,0003,465,143,0004,084,669,0004,100,711,0004,271,127,0004,801,292,0005,481,341,0006,413,199,0007,816,218,0008,661,744,000
Net income
70m
-12.95%
16,285,000-3,552,00047,032,00031,640,00053,152,00034,382,00029,657,00040,586,00020,353,000-52,117,000-21,182,000-48,963,000-112,720,000-9,734,00011,978,00052,334,00078,192,00080,874,00070,397,000
CFO
261m
+106.53%
-15,631,000-98,496,000-162,820,00011,027,00080,249,00044,404,00029,876,0008,934,000-90,119,00058,866,00059,265,000-107,293,000-51,826,000-55,845,000126,923,00039,344,000107,576,000126,322,000260,899,000
Dividend
Jan 02, 20240.27004 BRL/sh
Earnings
Mar 06, 2025

Profile

Profarma Distribuidora de Produtos Farmacêuticos S.A., together with its subsidiaries, engages in the distribution and retail sale of pharmaceutical and hospital products in Brazil. The company operates through Distribution, and Retail segments. It provides branded medicines, generic drugs, and over-the-counter (OTC) medicines; personal hygiene, beauty, and cosmetic products, such as shampoos, conditioners, treatment creams and hair dyes, diapers and children's products, soaps , deodorants, oral care products, sunscreens, male products, cosmetics, makeup and skin products, and others; and hospital products, including injectable and infusion drugs for oncology, endocrinology, rheumatology, infectology, hematology, and other specialties. The company also offers vaccines for influenza, HPV, meningitis, hepatitis, chickenpox, dengue, and other diseases; special medicines intended for the treatment of rare and complex diseases; exclusive hygiene and beauty products, vitamins, and workshops products under the Nº21, GOnutri, and Bem Básico brands; and convenience products, including food products, pressure gauges, scales, and related products. In addition, it provides complementary services, such as promotional and logistical support, implementation of promotional campaigns, product recall, development of customized projects to offer laboratories solutions, and management of clinical procedures. As of December 31, 2019, the company operated eleven distribution centers located in the states of Alagoas, Bahia, Espírito Santo, Goiás, Minas Gerais, Paraíba, Paraná, Pernambuco, Rio Grande do Sul, Rio de Janeiro, and São Paulo, as well as approximately 196 stores in the states of Rio de Janeiro, Goiás, Tocantins, Mato Grosso, and Distrito Federal under the Drogarias Tamoio, Drogasmil, Farmalife, and Rede Rosário brands. The company was founded in 1961 and is headquartered in Rio de Janeiro, Brazil.
IPO date
Oct 26, 2006
Employees
Domiciled in
BR
Incorporated in
BR

Valuation

Title
BRL in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
8,661,744
10.82%
7,816,218
21.88%
6,413,199
17.00%
Cost of revenue
8,416,126
6,782,708
5,997,288
Unusual Expense (Income)
NOPBT
245,618
1,033,510
415,911
NOPBT Margin
2.84%
13.22%
6.49%
Operating Taxes
3,735
(6,070)
(30,367)
Tax Rate
1.52%
NOPAT
241,883
1,039,580
446,278
Net income
70,397
-12.95%
80,874
3.43%
78,192
49.41%
Dividends
(31,229)
(29,117)
Dividend yield
4.34%
4.02%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
298,788
221,920
206,837
Long-term debt
1,208,704
1,162,799
1,128,474
Deferred revenue
Other long-term liabilities
67,127
54,326
62,016
Net debt
1,268,708
1,154,819
1,106,548
Cash flow
Cash from operating activities
260,899
126,322
107,576
CAPEX
(14,012)
(10,510)
(13,547)
Cash from investing activities
(96,582)
(21,740)
(86,409)
Cash from financing activities
(153,829)
(109,844)
(204,442)
FCF
76,008
872,269
216,094
Balance
Cash
193,743
183,255
188,517
Long term investments
45,041
46,645
40,246
Excess cash
Stockholders' equity
1,555,392
1,683,935
1,589,605
Invested Capital
2,749,850
2,499,726
2,416,743
ROIC
9.22%
42.29%
19.33%
ROCE
8.80%
40.67%
16.94%
EV
Common stock shares outstanding
122,611
122,611
122,611
Price
5.87
59.95%
3.67
-37.80%
5.90
-3.28%
Market cap
719,727
59.95%
449,982
-37.80%
723,405
-3.28%
EV
2,279,112
1,924,381
2,219,771
EBITDA
394,138
1,171,731
541,797
EV/EBITDA
5.78
1.64
4.10
Interest
168,313
149,196
76,156
Interest/NOPBT
68.53%
14.44%
18.31%